INDIAGLYCO India Glycols Q1 FY27 results (Apr–Jun 2026) and concall
India Glycols Limited reported a strong Q1 FY27 with a 9% increase in net revenue to INR1,130 crores and a 13% rise in EBITDA to INR170 crores, driven by balanced portfolio performance and improved profitability. The company saw exceptional growth in Ennature Bio Pharma and continued progress in its demerger, while navigating challenges from raw material volatility and freight costs.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 8.6%, net profit up 45.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 961 | 975 | 863 | 1,040 | 1,091 +14% | 1,102 +13% | 978 +13% | 1,129 +9% |
| EBITDA | 116 | 124 | 144 | 148 | 158 +36% | 176 +42% | 164 +14% | 170 +15% |
| Net profit | 39 | 44 | 50 | 53 | 54 +38% | 65 +48% | 110 +120% | 77 +45% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.





